Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 10/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232912 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1232629 | 0.98 | HDAC6 (0.97) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL6386847 | 0.93 | HDAC6 (0.88) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| Trifluoroacetic Acid SCHEMBL29825044 | 0.92 | HDAC6 (0.84) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL6387051 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL6385727 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL6389005 | 0.89 | HDAC6 (0.97) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL2226579 | 0.89 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL4922807 | 0.88 | HDAC1 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL4258321 | 0.88 | HDAC1 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20050119305-A1 | Il-6 production inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | claimed |
| CN-115141123-B | Compound, preparation method thereof and application thereof in preparation of dual inhibitors of histone deacetylase and epoxide hydrolase | 沈阳药科大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-117843548-A | Benzyl indole HDAC inhibitor and pharmaceutical application thereof | 南京医科大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-115141123-A | Compound, preparation method thereof and application thereof in preparation of histone deacetylase and epoxide hydrolase dual inhibitor | 沈阳药科大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-2839037-B1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1443928-B1 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN KETTERING INST CANCER (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20050119305-A1 | Il-6 production inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 6/4885 |
| US-20050119305-A1 | Il-6 production inhibitors | IL6, IL6ST, PADI6 | HDAC6 2866/4885HDAC1 1343/4885HDAC8 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.